# Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.

> **NCT04621422** · — · UNKNOWN · sponsor: **University Hospital, Bordeaux** · enrollment: 60 (estimated)

## Conditions studied

- Neuro-Degenerative Disease

## Interventions

- **BIOLOGICAL:** Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1

## Key facts

- **NCT ID:** NCT04621422
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2022-06
- **Final completion:** 2023-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04621422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04621422, "Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04621422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*